228 related articles for article (PubMed ID: 33826602)
21. Potential therapeutic targets in ARID1A-mutated cancers.
Bitler BG; Fatkhutdinov N; Zhang R
Expert Opin Ther Targets; 2015; 19(11):1419-22. PubMed ID: 26125128
[TBL] [Abstract][Full Text] [Related]
22. Chromatin accessibility underlies synthetic lethality of SWI/SNF subunits in ARID1A-mutant cancers.
Kelso TWR; Porter DK; Amaral ML; Shokhirev MN; Benner C; Hargreaves DC
Elife; 2017 Oct; 6():. PubMed ID: 28967863
[TBL] [Abstract][Full Text] [Related]
23. [Chromatin remodeling defects and cancer: the SWI/SNF example].
Bourdeaut F; Bièche I
Bull Cancer; 2012 Dec; 99(12):1133-40. PubMed ID: 23222069
[TBL] [Abstract][Full Text] [Related]
24. Chromatin remodeling mediated by ARID1A is indispensable for normal hematopoiesis in mice.
Han L; Madan V; Mayakonda A; Dakle P; Woon TW; Shyamsunder P; Nordin HBM; Cao Z; Sundaresan J; Lei I; Wang Z; Koeffler HP
Leukemia; 2019 Sep; 33(9):2291-2305. PubMed ID: 30858552
[TBL] [Abstract][Full Text] [Related]
25. ARID1A ablation leads to multiple drug resistance in ovarian cancer via transcriptional activation of MRP2.
Luo Q; Wu X; Zhang Y; Shu T; Ding F; Chen H; Zhao P; Chang W; Zhu X; Liu Z
Cancer Lett; 2018 Jul; 427():9-17. PubMed ID: 29660381
[TBL] [Abstract][Full Text] [Related]
26. MYC assembles and stimulates topoisomerases 1 and 2 in a "topoisome".
Das SK; Kuzin V; Cameron DP; Sanford S; Jha RK; Nie Z; Rosello MT; Holewinski R; Andresson T; Wisniewski J; Natsume T; Price DH; Lewis BA; Kouzine F; Levens D; Baranello L
Mol Cell; 2022 Jan; 82(1):140-158.e12. PubMed ID: 34890565
[TBL] [Abstract][Full Text] [Related]
27. Inhibition of the ATM/Chk2 axis promotes cGAS/STING signaling in ARID1A-deficient tumors.
Wang L; Yang L; Wang C; Zhao W; Ju Z; Zhang W; Shen J; Peng Y; An C; Luu YT; Song S; Yap TA; Ajani JA; Mills GB; Shen X; Peng G
J Clin Invest; 2020 Nov; 130(11):5951-5966. PubMed ID: 33016929
[TBL] [Abstract][Full Text] [Related]
28. Remodeling of the ARID1A tumor suppressor.
Luo Q; Wu X; Liu Z
Cancer Lett; 2020 Oct; 491():1-10. PubMed ID: 32738271
[TBL] [Abstract][Full Text] [Related]
29. Identification of a novel GR-ARID1a-P53BP1 protein complex involved in DNA damage repair and cell cycle regulation.
Stubbs FE; Flynn BP; Rivers CA; Birnie MT; Herman A; Swinstead EE; Baek S; Fang H; Temple J; Carroll JS; Hager GL; Lightman SL; Conway-Campbell BL
Oncogene; 2022 Dec; 41(50):5347-5360. PubMed ID: 36344675
[TBL] [Abstract][Full Text] [Related]
30. Epigenetic driver mutations in ARID1A shape cancer immune phenotype and immunotherapy.
Li J; Wang W; Zhang Y; Cieślik M; Guo J; Tan M; Green MD; Wang W; Lin H; Li W; Wei S; Zhou J; Li G; Jing X; Vatan L; Zhao L; Bitler B; Zhang R; Cho KR; Dou Y; Kryczek I; Chan TA; Huntsman D; Chinnaiyan AM; Zou W
J Clin Invest; 2020 May; 130(5):2712-2726. PubMed ID: 32027624
[TBL] [Abstract][Full Text] [Related]
31. ARID1A facilitates KRAS signaling-regulated enhancer activity in an AP1-dependent manner in colorectal cancer cells.
Sen M; Wang X; Hamdan FH; Rapp J; Eggert J; Kosinsky RL; Wegwitz F; Kutschat AP; Younesi FS; Gaedcke J; Grade M; Hessmann E; Papantonis A; Strӧbel P; Johnsen SA
Clin Epigenetics; 2019 Jun; 11(1):92. PubMed ID: 31217031
[TBL] [Abstract][Full Text] [Related]
32. Inactivating ARID1A Tumor Suppressor Enhances TERT Transcription and Maintains Telomere Length in Cancer Cells.
Suryo Rahmanto Y; Jung JG; Wu RC; Kobayashi Y; Heaphy CM; Meeker AK; Wang TL; Shih IeM
J Biol Chem; 2016 Apr; 291(18):9690-9. PubMed ID: 26953344
[TBL] [Abstract][Full Text] [Related]
33. The Primary Effect on the Proteome of ARID1A-mutated Ovarian Clear Cell Carcinoma is Downregulation of the Mevalonate Pathway at the Post-transcriptional Level.
Goldman AR; Bitler BG; Schug Z; Conejo-Garcia JR; Zhang R; Speicher DW
Mol Cell Proteomics; 2016 Nov; 15(11):3348-3360. PubMed ID: 27654507
[TBL] [Abstract][Full Text] [Related]
34. ARID1A mutant ovarian clear cell carcinoma: A clear target for synthetic lethal strategies.
Caumanns JJ; Wisman GBA; Berns K; van der Zee AGJ; de Jong S
Biochim Biophys Acta Rev Cancer; 2018 Dec; 1870(2):176-184. PubMed ID: 30025943
[TBL] [Abstract][Full Text] [Related]
35. ARID1A Deficiency Impairs the DNA Damage Checkpoint and Sensitizes Cells to PARP Inhibitors.
Shen J; Peng Y; Wei L; Zhang W; Yang L; Lan L; Kapoor P; Ju Z; Mo Q; Shih IeM; Uray IP; Wu X; Brown PH; Shen X; Mills GB; Peng G
Cancer Discov; 2015 Jul; 5(7):752-67. PubMed ID: 26069190
[TBL] [Abstract][Full Text] [Related]
36. Acute depletion of the ARID1A subunit of SWI/SNF complexes reveals distinct pathways for activation and repression of transcription.
Blümli S; Wiechens N; Wu MY; Singh V; Gierlinski M; Schweikert G; Gilbert N; Naughton C; Sundaramoorthy R; Varghese J; Gourlay R; Soares R; Clark D; Owen-Hughes T
Cell Rep; 2021 Nov; 37(5):109943. PubMed ID: 34731603
[TBL] [Abstract][Full Text] [Related]
37. Landscape of chromatin remodeling gene alterations in endometrial carcinoma.
Momeni-Boroujeni A; Vanderbilt C; Yousefi E; Abu-Rustum NR; Aghajanian C; Soslow RA; Ellenson LH; Weigelt B; Murali R
Gynecol Oncol; 2023 May; 172():54-64. PubMed ID: 36958196
[TBL] [Abstract][Full Text] [Related]
38. Targeting ARID1A-mutant colorectal cancer: depletion of ARID1B increases radiosensitivity and modulates DNA damage response.
Niedermaier B; Sak A; Zernickel E; Xu S; Groneberg M; Stuschke M
Sci Rep; 2019 Dec; 9(1):18207. PubMed ID: 31796878
[TBL] [Abstract][Full Text] [Related]
39. The chromatin remodeling gene ARID1A is a new prognostic marker in clear cell renal cell carcinoma.
Lichner Z; Scorilas A; White NM; Girgis AH; Rotstein L; Wiegand KC; Latif A; Chow C; Huntsman D; Yousef GM
Am J Pathol; 2013 Apr; 182(4):1163-70. PubMed ID: 23416164
[TBL] [Abstract][Full Text] [Related]
40. The emerging roles of ARID1A in tumor suppression.
Wu RC; Wang TL; Shih IeM
Cancer Biol Ther; 2014 Jun; 15(6):655-64. PubMed ID: 24618703
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]